Reset filters
  • 28 October 2005

Second company halts CCR5 inhibitor study in another blow to new drug class

Read the article
  • 19 October 2005

New boosted PIs should be used with T-20 for maximum impact, say new US guidelines

Read the article
  • 28 September 2005

Treatment interruption delivers no benefit for most heavily treated, despite resistance loss

Read the article
  • 27 September 2005

Discordant CD4 increase of 25 cells/mm3 confers clinical benefit despite advanced disease

Read the article
  • 16 September 2005

GSK halts chemokine inhibitor trial due to safety fears

Read the article
  • 29 July 2005

IAS: Needle-free T-20 delivery reduces, but does not eliminate, injection site reactions (corrected)

Read the article
  • 28 July 2005

IAS: Tipranavir combined with T-20 achieves good virologic results in the highly treatment experienced

Read the article
  • 28 July 2005

IAS: Remaining on 3TC despite resistance leads to better immunological and clinical outcomes

Read the article
  • 1 July 2005

Pfizer discontinues capravirine development

Read the article

Receive the latest HIV research and conference news

Complete this form to receive regular email bulletins including the latest HIV research and conference news from aidsmap and/or updates from Terrence Higgins Trust.

Get regular email bulletins

Please let us know how you'd like to be contacted by ticking the options below.